Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open Label Extension Study of Pegunigalsidase Alfa Every 4 Weeks in Fabry Disease
2024-516735-27-00Phase 3Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Sep 2024
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, PEGylated Peptides → Modified Peptides → Peptides
- Countries
- 7
01
Overview
Phase 3, open-label, single-arm trial of pegunigalsidase alfa in Fabry disease (FD), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Safety and Efficacy. Started Sep 2024; status: completed.
02
Drugs
pegunigalsidase alfa
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on 2024-516735-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516735-27-00.